Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Other Accumulated Expenses (2023 - 2026)

Immunovant filings provide 3 years of Other Accumulated Expenses readings, the most recent being $273000.0 for Q1 2025.

  • Quarterly Other Accumulated Expenses rose 1720.0% to $273000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $273000.0 through Mar 2025, up 1720.0% year-over-year, with the annual reading at $273000.0 for FY2025, 1720.0% up from the prior year.
  • Other Accumulated Expenses hit $273000.0 in Q1 2025 for Immunovant, up from $15000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $350000.0 in Q1 2023 and bottomed at $15000.0 in Q1 2024.
  • Average Other Accumulated Expenses over 3 years is $212666.7, with a median of $273000.0 recorded in 2025.
  • The largest annual shift saw Other Accumulated Expenses tumbled 95.71% in 2024 before it soared 1720.0% in 2025.
  • Immunovant's Other Accumulated Expenses stood at $350000.0 in 2023, then tumbled by 95.71% to $15000.0 in 2024, then soared by 1720.0% to $273000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Other Accumulated Expenses are $273000.0 (Q1 2025), $15000.0 (Q1 2024), and $350000.0 (Q1 2023).